Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0000875320-25-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-14 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $463.46 | -6,553 | 129.4K | -5% | -$3.04M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-14 | F | D | 6,553 | $463.46 | 129,380 | D | — | — |